The Cardiovascular Research Foundation (CRF) presents 28 studies at TCT 2026, highlighting advances in minimally invasive interventions, pharmaceutical therapies, and breakthrough technologies. Key findings include improved outcomes for patients with heart and vascular disease.
Igor F. Palacios, MD, is honored for his groundbreaking work in structural heart disease interventions, including mitral balloon valvuloplasty and the percutaneous pericardial window technique. He has mentored hundreds of physician leaders worldwide through his kindness, generosity, and passion for patient-centered care.
New York Valves 2026 will unveil groundbreaking clinical science and innovation in transcatheter aortic valve replacement and mitral/tricuspid valve therapies. The conference features 22 late-breaking clinical science presentations that aim to transform the treatment of structural heart disease.
Dr. Rebecca T. Hahn, MD, is the first imager to receive the TCT Geoffrey O. Hartzler Master Operator Award for her groundbreaking work in imaging structural heart procedures. Her unparalleled expertise has redefined the role of imaging in cardiovascular care.
Patrick T. O'Gara, a master clinician and educator, will receive the TCT 2026 Career Achievement Award for his groundbreaking work in interventional cardiology. The award recognizes his clinical excellence, pioneering research, and mentorship of the next generation of physicians.
Registration is now open for TCT 2026, the annual scientific symposium of CRF, taking place October 31 - November 3 in San Diego. The event will feature a dynamic program with groundbreaking research and expert-led tutorials.
A new study published in TCT 2025 reveals that at least 4.7 million people aged 65-85 living in the US have moderate or greater valvular heart disease (VHD), and at least 10.6 million have clinically significant VHD. The prevalence of VHD increases with advanced age, highlighting the need for screening and treatment programs.
A new sirolimus-eluting balloon has been shown to be noninferior to traditional treatments for in-stent restenosis. The study, presented at TCT 2025, found the balloon to be safe and effective for treating ISR without adding extra layers of stents.
The merger strengthens CRF's leadership in medtech, integrating Fogarty's expertise in early-stage innovation. The unified platform will accelerate breakthroughs into patient care, driving global progress in cardiovascular medicine.
The study found that cutting balloon angioplasty is noninferior to intravascular lithotripsy in treating calcified coronary artery disease. The procedure is also less costly, making it a reasonable strategy for managing significantly calcified lesions.
A study found that super-high-pressure non-compliant balloons (NCB) are non-inferior to IVL balloon catheters for lesion preparation and stent expansion in severely calcified lesions. The results showed similar safety profiles and efficacy across various patient subgroups.
A large international study found that utilizing sirolimus-eluting balloons with bailout stenting only if necessary was noninferior to routine DES implantation for treating de novo coronary artery disease. The results showed comparable outcomes, including low rates of cardiac death and target vessel myocardial infarction.
The Cardiovascular Research Foundation (CRF) has announced the 2025 SET-10 Rankings, honoring institutions whose groundbreaking research is shaping the future of cardiovascular care. The rankings recognize academic and medical institutions that are advancing the science and improving patient outcomes.
The TCT AI Lab equips clinicians with skills to integrate AI into clinical practice, advancing precision, efficiency, and patient outcomes. The initiative is made possible by a generous grant from the Jon DeHaan Foundation.
Dr. Collet joins CRF to accelerate integration of cutting-edge research into clinical practice and expand global leadership in cardiovascular education. He will lead efforts to unify translational science, technological innovation, and education.
Late-breaking clinical trials and science at TCT 2025 will present pivotal data on novel therapies, devices, and techniques aimed at preventing and treating cardiovascular conditions. The symposium delivers high-impact findings that shape clinical practice and enhance outcomes for patients with heart and vascular disease.
Dr. Kenneth Rosenfield is a distinguished interventional cardiologist recognized for his seminal work in endovascular therapy and pioneering innovative techniques. He has made significant contributions to the field of vascular medicine, including the development of self-expanding stents and drug-coated balloons.
Stephan Windecker, a world-renowned cardiologist, will be honored with the TCT 2025 Career Achievement Award for his extraordinary contributions to interventional cardiology. His extensive research has shaped clinical practice worldwide and influenced the future of cardiovascular medicine.
TCT 2025 will take place October 25-28, 2025, at the Moscone Center in San Francisco, California. The event will feature acute interventions, breakthrough technologies, and cutting-edge research driving the next era of cardiovascular care.
Josep Rodés-Cabau takes over as Editor-in-Chief of Structural Heart: The Journal of the Heart Team, following Anthony N. DeMaria's retirement. Dr. Rodés-Cabau is a world-renowned expert in structural heart disease with extensive research and academic experience.
The Cardiovascular Research Foundation will host THT 2025, showcasing late-breaking clinical science presentations on transcatheter approaches to managing a wide spectrum of heart failure patients. Four dedicated sessions feature exclusive first-release data from pivotal studies and dynamic discussions on controversies in clinical trials.
The summit features live case demonstrations, interactive debates, hands-on training, and the latest evidence-based practices in structural heart care. Attendees will witness innovation in action, exploring breakthroughs in surgical techniques, transcatheter interventions, and personalized treatment strategies.
Dr. Jeffrey Popma joins CRF as Chief Scientific and Strategic Officer, bringing decades of clinical and research experience to drive forward pivotal programs and initiatives. His leadership will shape CRF's future and fuel innovation at the Clinical Trials Center.
Symbiosis has developed an adjustable TMVR system, ValSync, which can adapt to complex anatomies. The company aims to overcome current limitations and improve patient eligibility, safety, and procedure time with its three-step process.
The CLEAR SYNERGY (OASIS 9) trial found that routine colchicine use did not reduce cardiovascular death, myocardial infarction, stroke, or ischemia-driven revascularization after acute myocardial infarction. Colchicine therapy was associated with a significant reduction in C-reactive protein levels.
A randomized trial found that large-bore mechanical thrombectomy was superior to catheter-directed thrombolysis in reducing clinical deterioration, ICU admissions, and readmissions. LBMT also showed faster symptom improvement and shorter hospital stays compared to CDT.
A randomized trial found early TAVR to be safe and effective for patients with asymptomatic severe AS, reducing the risk of composite endpoints and favorable health status outcomes. Patients who received early TAVR had better left-ventricular and left-atrial health compared to those on clinical surveillance.
The TAVR UNLOAD study found that transcatheter aortic valve replacement did not significantly affect the primary composite endpoint in patients with systolic heart failure and moderate aortic stenosis. However, TAVR improved quality of life compared to clinical AS surveillance.
A new study found that early aortic valve intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis did not reduce the incidence of all-cause death or unplanned aortic stenosis hospitalization. However, it did show benefits in reducing emergency hospitalizations and preventing symptom development.
The ECLIPSE trial found that routine orbital atherectomy had similar outcomes as conventional balloon angioplasty before stent implantation. Procedural complications were largely similar between groups, with no reduction in target vessel failure.
The Cardiovascular Research Foundation recognizes 29 leading institutions for their contributions to groundbreaking research advancing interventional cardiovascular medicine. The 2024 SET-10 rankings celebrate institutions making significant impacts across various categories, including basic science and clinical research.
The third annual TCT MedTech Innovation Forum will address pressing cardiovascular medicine challenges and unveil disruptive solutions. Visionary leaders from the medtech landscape will convene to explore bold solutions, share pioneering insights, and shape the future of cardiovascular care.
TCT 2024 features groundbreaking research on minimally invasive techniques, pharmaceuticals, technologies, and devices to treat or prevent cardiovascular disease. The event showcases the latest advancements in interventional cardiology and offers a platform for clinicians to learn about new interventions and strategies.
The conference will feature 12 late-breaking clinical trials and science presentations on transcatheter aortic valve replacement, mitral and tricuspid devices and techniques. Data from these trials will guide the selection of patients who will benefit most from procedures and define optimal treatment strategies.
Jeffrey W. Moses, MD, is recognized for advancing the field of interventional cardiovascular medicine through technical excellence and leadership. Dr. Moses has performed over 20,000 interventional procedures and made significant contributions to clinical research and educational activities in interventional vascular therapy.
Robert A. Harrington, MD, will be honored for his groundbreaking work in clinical research and clinical excellence. He has made extraordinary contributions to the field of interventional cardiology, transforming cardiovascular care through his pioneering research and mentorship.
The American Association for Thoracic Surgery (AATS) and Cardiovascular Research Foundation (CRF) will collaborate on the development of New York Valves 2024, focusing on advances in surgical approaches and techniques in valve disease. The summit will feature expert discussions, live-case demonstrations, and hands-on training.
New York Valves: The Structural Heart Summit is a world-class educational experience for the field of structural heart interventions. The summit will showcase advanced techniques, evidence-based medicine, and live-case demonstrations, offering attendees an unparalleled opportunity to explore the newest techniques and technologies.
Thirty-two institutions earned the SET-10 distinction, with top ten recognized globally for their dedication to advancing scientific knowledge in interventional cardiovascular medicine. The rankings span six categories and acknowledge excellence within and outside the United States.
The Cardiovascular Research Foundation has announced the TCT 2023 late-breaking clinical trials, featuring 12 studies on minimally invasive techniques, pharmaceuticals, technologies, and devices. These trials aim to improve patient outcomes in cardiovascular disease, with a focus on safety and effectiveness.
The TCT MedTech Innovation Forum brings together clinicians, entrepreneurs, and industry stakeholders to identify clinical challenges and uncover opportunities for innovation in cardiovascular care. The forum features three comprehensive tracks addressing stakeholder interests and explores the role of digital health care dynamics.
The TCT 2023 Program Guide features four days of innovation and cutting-edge science in interventional cardiovascular medicine. The event marks 35 years of leading the field and will gather top researchers and clinicians to present evidence-based research.
TVT 2023 will feature 15 Late-Breaking Clinical Science studies highlighting advances in transcatheter aortic valve replacement and mitral, tricuspid, and left atrial appendage occlusion therapies. The meeting aims to guide the selection of patients who will benefit from these procedures and define optimal treatment strategies.
The program guide for TVT 2023 showcases over 200 world-renowned faculty experts, with a focus on clinical decision-making and strategies for treating valvular heart disease. The summit highlights the latest advances in transcatheter valve therapy and nonsurgical procedures.
Stuart J. Pocock, a renowned statistician, will receive the TCT Career Achievement Award for his groundbreaking work in interventional cardiology. His research has transformed patient care through evidence-based insights, improving survival and quality of life for heart disease patients worldwide.
William L. Lombardi, MD, receives the TCT Geoffrey O. Hartzler Master Operator Award for his technical excellence and leadership in complex coronary disease therapies. He is recognized for developing novel CTO techniques and technologies to improve patient outcomes.
A study using STS/ACC TVT Registry data found that most patients with severe mitral regurgitation (MR) and cardiogenic shock who underwent TEER achieved successful MR reduction, with associated lower mortality and heart failure hospitalizations at one year. Device success was linked to improved survival rates in a high-risk population.
The PASCAL transcatheter valve repair system showed non-inferiority compared to MitraClip in treating significant symptomatic DMR. Patients experienced improvements in functional and quality-of-life outcomes.
The TCT MedTech Innovation Forum is an intensive summit bringing together clinicians, entrepreneurs, investors, and regulators to identify clinical challenges and drive innovation in medtech. The agenda features interdisciplinary perspectives on unmet clinical needs, financing, regulatory policy, and evolving healthcare delivery models.
The new educational alliance will strengthen access to medical education and training for physicians, researchers, and healthcare professionals. The joint programs will focus on advancing the latest research in cardiovascular disease and interventional therapies.